Lv71
4980 积分 2022-04-22 加入
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial
1小时前
已完结
Development of Regulation and Policy for Cell Therapies in China
1个月前
已完结
Immunogenicity Risk Assessment of Process-Related Impurities in An Engineered T Cell Receptor Cellular Product
1个月前
已关闭
Clearance of residual genome editing components used for ex vivo genome-editing of allogeneic cell therapy products
1个月前
已完结
Microenvironmental regulation of solid tumour resistance to CAR T cell therapy
2个月前
已完结
The presence of CD5LOW+NK cells in normal controls and patients with pulmonary tuberculosis
2个月前
已完结
The increase of CD5LOW+NK cells in patients with multiple myeloma and plasmacytoma
2个月前
已关闭
In vivo chimeric antigen receptor (CAR)-T cell therapy
2个月前
已完结
T STEM -like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models
4个月前
已完结
Inosine induces stemness features in CAR-T cells and enhances potency
4个月前
已完结
皖公网安备34019202002308
